Delivery Order SPE2DB20D2104-SPE2DB25FMWBV
- Not listed
- The Defense Logistics Agency awarded a $7,300.63 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Valsartan-HCTZ 160-12.5 mg tablets (90-count) on June 2, 2025, with completion scheduled for June 3, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets in a quantity of 90 tablets, with a contract ceiling value of $1,393.20. This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $3,819.87 delivery order to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,542.97 to AmerisourceBergen Drug Corp for Valsartan-HCTZ 320-25 mg tablets (90-count supply). This competitively awarded, firm fixed-price delivery order was issued on August 15, 2025, with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters. As a child delivery order under a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Valsartan-HCTZ 160-25 mg tablets in quantities of 90 units, with a contract ceiling value of $11,676.65. This is a firm fixed-price delivery order with an ultimate completion date of September 17, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Valsartan-HCTZ 80-12.5 mg tablets in quantities of 90 units. This firm fixed-price delivery order, valued at $3,321.82, represents a non-competitive set-aside contract and is scheduled for completion by August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets in a quantity of 90 units, with a ceiling value of $1,697.07. This competitively awarded, firm fixed-price contract is classified as non-set-aside and was completed on August 5, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the delivery order from its location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets in a 90-count quantity, with a ceiling value of $8,641.99. This firm fixed-price delivery order, which is not set-aside designated, represents a continuation of AmerisourceBergen's pharmaceutical supply support under its larger contract vehicle with the DLA. Performance will be executed from the contractor's Conshohocken, Pennsylvania...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $77,079.86 to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Valsartan-HCTZ 320-12.5 mg tablets in quantities of 90 units. This firm fixed-price delivery order, which was not set-aside and competed openly, is scheduled for completion by September 12, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $34,068.09 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count supply). This competitive, non-set-aside delivery order represents a firm fixed price contract with a completion date of June 3, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Valsartan-HCTZ is a combination antihypertensive medication used to manage high...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMWBVDelivery Order
The Defense Logistics Agency awarded a $1,224.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Valsartan-HCTZ 160-12.5 mg tablets (90-count supply) on July 22, 2025, with completion scheduled for July 23, 2025. The contract represents a non-competitive, non-set-aside delivery order executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, supplying brand-name and generic medications across multiple therapeutic domains to military and veteran healthcare systems. This delivery order falls under AmerisourceBergen's prime Indefinite Delivery/Indefinite Quantity contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The IDC functions as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to deliver medications and medical supplies to support Department of Defense healthcare programs worldwide. The valsartan-HCTZ combination represents a common antihypertensive medication utilized throughout the military medical supply chain for hypertension management across the Defense Health Agency and associated military treatment facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 7/22/25 |